JP2009541204A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541204A5
JP2009541204A5 JP2008558572A JP2008558572A JP2009541204A5 JP 2009541204 A5 JP2009541204 A5 JP 2009541204A5 JP 2008558572 A JP2008558572 A JP 2008558572A JP 2008558572 A JP2008558572 A JP 2008558572A JP 2009541204 A5 JP2009541204 A5 JP 2009541204A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
chain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558572A
Other languages
English (en)
Japanese (ja)
Other versions
JP5028635B2 (ja
JP2009541204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2006/317155 external-priority patent/WO2007148417A1/en
Publication of JP2009541204A publication Critical patent/JP2009541204A/ja
Publication of JP2009541204A5 publication Critical patent/JP2009541204A5/ja
Application granted granted Critical
Publication of JP5028635B2 publication Critical patent/JP5028635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558572A 2006-06-21 2006-08-24 Fzd10に対する腫瘍標的化モノクローナル抗体とその使用 Active JP5028635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81525706P 2006-06-21 2006-06-21
US60/815,257 2006-06-21
PCT/JP2006/317155 WO2007148417A1 (en) 2006-06-21 2006-08-24 Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Publications (3)

Publication Number Publication Date
JP2009541204A JP2009541204A (ja) 2009-11-26
JP2009541204A5 true JP2009541204A5 (https=) 2011-07-28
JP5028635B2 JP5028635B2 (ja) 2012-09-19

Family

ID=37616924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558572A Active JP5028635B2 (ja) 2006-06-21 2006-08-24 Fzd10に対する腫瘍標的化モノクローナル抗体とその使用

Country Status (10)

Country Link
US (2) US8221751B2 (https=)
EP (2) EP2386577A3 (https=)
JP (1) JP5028635B2 (https=)
KR (1) KR101351208B1 (https=)
CN (1) CN101573383B (https=)
BR (1) BRPI0621800B8 (https=)
CA (1) CA2655289C (https=)
ES (1) ES2405618T3 (https=)
RU (1) RU2412203C2 (https=)
WO (1) WO2007148417A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
WO2008061020A2 (en) * 2006-11-14 2008-05-22 Novartis Ag Methods of treating, diagnosing or detecting cancer
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
JP5407042B2 (ja) * 2009-12-16 2014-02-05 公益財団法人ヒューマンサイエンス振興財団 セセルニン−1の使用、滑膜肉腫の予後予測方法及び検査用試薬キット
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2013025446A2 (en) * 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
AU2015314771B2 (en) 2014-09-12 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Wnt signaling agonist molecules
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 修飾された重鎖定常領域を含む抗体
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US10416165B2 (en) 2015-08-10 2019-09-17 National University Corporation University Of Toyama Method for producing antigen specific monoclonal antibody
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
EP3988111A1 (en) * 2016-04-01 2022-04-27 Innovative Cellular Therapeutics Holdings, Ltd. Use of chimeric antigen receptor modified cells to treat cancer
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
TWI762516B (zh) * 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對fzd10之單株抗體及其用途
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
US20210292422A1 (en) 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
CA3104868A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング, インコーポレイテッド 肝臓特異的Wntシグナル増強分子およびその使用
CN115724977B (zh) * 2022-11-04 2025-06-13 中国科学技术大学 针对人卷曲受体的单克隆抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
GB9414580D0 (en) 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
US5994098A (en) * 1997-06-02 1999-11-30 Smithkline Beecham Corporation Human 7-TM receptor similar to murine frizzled-6 gene
EP0943684A3 (en) 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
GB9819681D0 (en) 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
CA2405431A1 (en) 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
CA2456008A1 (en) 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
US6964849B2 (en) * 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
CA2433742A1 (en) 2001-01-11 2002-07-18 Curagen Corporation Proteins and nucleic acids encoding same
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002317105A1 (en) 2001-07-05 2003-01-21 University Of British Columbia Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2003256079A1 (en) 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
WO2004032838A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
JP4691626B2 (ja) * 2003-07-11 2011-06-01 オンコセラピー・サイエンス株式会社 滑膜肉腫の治療方法
CN1993466A (zh) 2004-08-05 2007-07-04 国立大学法人东京大学 利用针对FZD10的siRNA治疗滑膜肉瘤的方法

Similar Documents

Publication Publication Date Title
JP2009541204A5 (https=)
RU2009101788A (ru) Направленные на опухоль моноклональные антитела против fzd10 и их применение
RU2011103199A (ru) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
JP6586648B2 (ja) 抗プログルカゴン抗体
US20150111250A1 (en) Methods and compositions for modulating tumor cell activity
JP2008538289A5 (https=)
JP6342812B2 (ja) 鉄関連障害を診断および治療するための組成物および方法
JP2005528099A5 (https=)
JP5941615B2 (ja) ヒトcxcl1タンパク質の免疫学的測定方法
JP2020526478A5 (https=)
JP2010523096A5 (https=)
JP2020534830A5 (https=)
JP2019513018A5 (https=)
JP2012012402A5 (https=)
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
JP2005515963A5 (https=)
JP2005528914A5 (https=)
JP6081699B2 (ja) Il−28bの分析方法
JP2010505426A (ja) 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
JP2018518151A5 (https=)
JP2022531454A5 (https=)
JP2017538439A5 (https=)
JP2007526891A5 (https=)
JP2021521267A5 (https=)
CN114174341A (zh) 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法